Utah Medical Products, Inc.
NASDAQ:UTMDMedical - Instruments & Supplies
+$1.10 today
- Market cap
- $205.81M
- Beta
- 0.37
- P/E (TTM)
- 19.6
- EPS (TTM)
- $3.41
- Dividend yield
- 1.85%
Volume 0.02M
Average 0.01M
UTMD Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Utah Medical Products, Inc.NASDAQ: UTMD
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $120K rose 46.3% year over year, behind the +58.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 8.1% from the prior quarter. Over 3 fiscal years it compounded at +26.8% a year.
Context
- Stock-based compensation amounted to 1.0% of revenue in FY2025, up 0.3 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +46.3% toward the trailing-twelve-month pace of +58.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 373K USD
- Year-over-year change
- +45.7%
- 4-year CAGR
- +22.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 373K | +45.7% |
| FY2024 | 2024-12-31 | 256K | +13.8% |
| FY2023 | 2023-12-31 | 225K | +23.0% |
| FY2022 | 2022-12-31 | 183K | +10.2% |
| FY2021 | 2021-12-31 | 166K | — |
Stock-Based Compensation vs competitors
How UTMD compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +58.7% is the 2nd highest of 11, against a peer median of -10.1%.
- Stock-based compensation amounts to 1.1% of revenue for UTMD, versus a peer median of 5.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.99M USD | -15.0% | -30.6% | 46.9% | |
| LTM Mar 2026 | $11.45M USD | -1.6% | -90.4% | 10.1% | |
| LTM Mar 2026 | $9.42M USD | +38.0% | +88.2% | 1524.4% | |
| LTM Mar 2026 | $5.55M USD | +98.0% | +9.0% | 29.4% | |
| LTM Mar 2026 | $5.4M USD | -5.3% | -7.8% | 3.6% | |
| LTM Mar 2026 | $4.49M USD | -0.5% | +4.5% | 3.2% | |
| LTM Mar 2026 | $1.98M USD | -24.3% | -4.1% | 4.6% | |
| LTM Mar 2026 | €887K EUR | -82.2% | — | 5.4% | |
| LTM Mar 2026 | $411K USD | +58.7% | +26.8% | 1.1% | |
| LTM Mar 2026 | $141K USD | -98.0% | — | 0.1% | |
| LTM Mar 2026 | $8K USD | -100.3% | +3.3% | 0.0% | |
| Peer median (excluding UTMD) | — | -10.1% | -0.4% | 5.0% | |
Competitors are the stored peer set for UTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 14.79M | 16.47M | 16.64M | 13.87M | 11.29M |
| Depreciation & Amortization | 7.28M | 7.08M | 6.37M | 2.85M | 3.01M |
| Deferred Income Tax | (92K) | (401K) | (681K) | (338K) | (659K) |
| Stock-Based Compensation | 166K | 183K | 225K | 256K | 373K |
| Change in Working Capital | (1.01M) | (2.23M) | (233K) | (1.8M) | 317K |
| Accounts Receivables | (1.13M) | (525K) | 2.27M | (781K) | 333K |
| Inventory | (485K) | (2.35M) | (670K) | 587K | 1.2M |
| Accounts Payables | (23K) | 464K | (456K) | (73K) | 211K |
| Other Working Capital | 632K | 188K | (1.38M) | (1.54M) | (1.42M) |
| Other Non-Cash Items | 63K | 36K | (33K) | (4K) | 367K |
| Operating Cash Flow | 21.2M | 21.15M | 22.28M | 14.83M | 14.69M |
| Capital Expenditures | (552K) | (818K) | (639K) | (235K) | (371K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (9K) | 0 | 27K | 0 |
| Investing Cash Flow | (552K) | (818K) | (639K) | (208K) | (371K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (2.5M) | 0 | (19.97M) | (8.36M) |
| Dividends Paid | (11.47M) | (3.16M) | (4.28M) | (4.26M) | (3.98M) |
| Other Financing Activities | 560K | 174K | 117K | 390K | 0 |
| Financing Cash Flow | (10.91M) | (5.48M) | (4.17M) | (23.84M) | (12.34M) |
| Effect of Forex Changes | (362K) | (767K) | 339K | (677K) | 797K |
| Net Change in Cash | 9.38M | 14.08M | 17.82M | (9.89M) | 2.78M |
| Free Cash Flow | 20.65M | 20.33M | 21.64M | 14.6M | 14.32M |
Utah Medical Products, Inc.
NASDAQ:UTMD
Intrinsic Alpha fair value
Locked
Current Price
$72.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.